Bengaluru: Another quarter and another downward revision in growth. Infosys Ltd is expected by at least three brokerages to scale down its full-year dollar revenue growth for the third time this year when India’s second-largest software firm declares its third quarter results on Friday. This is not surprising, considering the negative cross currency impact and also partially, on account of management’s inability to give a firm guidance. Still, 2015-16 is turning out to be roller-coaster ride for Infosys chief executive officer (CEO) Vishal Sikka. Till a year ago, Sikka seemed to have settled well and appeared to be enjoying his job (from playing cricket with employees in Mysuru to the after-results parties with senior management ranks). By December, Sikka came across as a different boss, unhappy with the progress made by the company, and heard telling his colleagues how he has been unable to implement things he had planned when he took over the current job in August 2014. I...
Noida, Uttar Pradesh, India The wait is finally over! India’s largest multinational flexible packaging materials and Solution Company Uflex has unveiled ‘ASEPTOTM’ its Aseptic Liquid Packaging Brand. Uflex’s Aseptic Liquid Packaging manufacturing plant that will be commercially operational by April 2017 perfectly echoes Government of India’s Make in India ethos. ASEPTOTM is derived from the word aseptic which means sterile. Aseptic packaging ensures that food remains free from bacteria and other harmful microorganisms for a period of at least 8 months under room temperature. As shown in the image (3) above, aseptic packages are made by laminating Polyethylene with paperboard and aluminium foil. This multi-layered construction enables the carton to protect the contents from various factors responsible for spoilage, thereby preserving the product freshness and value. The aluminum foil layer is a strong barrier for O2 and light; The innermost layer made of pol...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets approved by the U.S. Food and Drug Administration (USFDA).“This launch is a testament to our core strengths in areas of research and development and intellectual property,” says Marc Kikuchi, Chief Executive Officer, North America Generics. “We are excited to be a part of forming the first generic market for Vimovo ® Tablets and to provide an affordable treatment alternative for patients.” The Vimovo ® (Naproxen and Esomeprazole Magnesium) Delayed-Release Tablets brand had U.S. sales of approximately $414 million MAT for the most recent twelve months ending in December 2019 according to IQVIA Health*.Dr. Reddy’s Naproxen and E...
Comments
Post a Comment